Author: Nichols Martin|| Date Published: March 31, 2021
The U.S. Army has reserved at least 100,000 doses of AstraZeneca’s AZD7442, a long-acting antibody product designed to prevent COVID-19 infection or treat the coronavirus disease, through a $204.9 million contract modification.
The service branch obligated the full amount using its fiscal 2021 research, development, test and evaluation funds, the Department of Defense said Tuesday.
Contract work will take place in Wilmington, Delaware, through Dec. 31.
AstraZeneca licensed the AZD7442 combination therapy of two long-acting antibodies from the Vanderbilt University Medical Center in Nashville, Tennessee, last year and engineered the drug using the company’s proprietary half-life extension technology.
A Phase III clinical trial is underway to evaluate the efficacy and safety of the LAAB combo product as a treatment for non-hospitalized COVID-19 patients.
Sonny Bhagowalia, assistant commissioner for information and technology and chief information officer at U.S. Customs and Border Protection, has received…
NextPoint Group expands intelligence-focused capabilities with UScontracting acquisition by adding expertise in cybersecurity, signals intelligence and data analysis for national…
